• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views

    7/18/24 2:31:40 PM ET
    $ABT
    $AGEN
    $CHUY
    $COMM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABT alert in real time by email

    U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday.

    The Dow traded down 1.08% to 40,752.05 while the NASDAQ fell 0.80% to 17,853.34. The S&P 500 also fell, dropping, 0.75% to 5,546.48.

    Check This Out: Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

    Leading and Lagging Sectors

    Energy shares jumped by 1.1% on Thursday.

    In trading on Thursday, health care shares fell by 1.6%.

    Top Headline

    Abbott Laboratories (NYSE:ABT) reported better-than-expected earnings for its second quarter on Thursday.

    The company posted sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 billion. Abbott's adjusted diluted earnings per share was $1.14, beating the analyst estimates of $1.10.

    Abbott said it projects full-year 2024 GAAP EPS of $3.30-$3.40 versus prior guidance of $3.25-$3.40, primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. The company forecasts adjusted EPS of $4.61-$4.71 versus the prior guidance of $4.55-$4.70 and consensus of $4.63.

    Equities Trading UP
                           

    • CommScope Holding Company, Inc. (NASDAQ:COMM) shares shot up 9% to $1.87. Amphenol announced plans to acquire mobile networks businesses from CommScope.
    • Shares of Silo Pharma, Inc. (NASDAQ:SILO) got a boost, surging 60% to $3.60. Silo Pharma said it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider.
    • Chuy’s Holdings, Inc. (NASDAQ:CHUY) shares were also up, gaining 48% to $37.33 after Darden Restaurants announced it will acquire the company.

    Equities Trading DOWN

    • Agenus Inc. (NASDAQ:AGEN) shares dropped 56% to $7.85 after the company announced the FDA discouraged an accelerated approval pathway at the end-of-Phase 2 meeting.
    • Shares of Leslie’s, Inc. (NASDAQ:LESL) were down 32% to $2.7850 after the company reported preliminary financial results for the third quarter and cut its full-year guidance. Multiple analysts also lowered price targets on the stock Thursday morning.
    • Torrid Holdings Inc. (NYSE:CURV) was down, falling 16% to $7.24 after Morgan Stanley downgraded the stock from Equal-Weight to Underweight and maintained its $5 price target.

    Also Check This Out: Nvidia, Electronic Arts And 2 Other Stocks Insiders Are Selling

    Commodities

    In commodity news, oil traded up 0.5% to $83.23 while gold traded down 0.1% at $2,458.60.

    Silver traded down 0.5% to $30.225 on Thursday, while copper fell 2.9% to $4.2815.

    Euro zone

    European shares closed mixed today. The eurozone's STOXX 600 fell 0.16%, Germany's DAX fell 0.45% and France's CAC 40 rose 0.21%. Spain's IBEX 35 Index rose 0.38%, while London's FTSE 100 rose 0.21%.

    Construction output in the Eurozone fell 2.4% year-over-year in May compared to a revised 1.5% decline in the prior month. Passenger car registrations in the European Union climbed 4.3% year-over-year to 1.1 million units in June.

    Regular pay in the U.K., excluding bonus payment, rose 5.7% year-over-year to GBP 643/week during the three months to May, while the unemployment rate came in unchanged at 4.4% from March to May.

    Asia Pacific Markets

    Asian markets closed mixed on Thursday, with Japan's Nikkei 225 dipping 2.36%, Hong Kong's Hang Seng Index gaining 0.22%, China's Shanghai Composite Index gaining 0.48% and India's S&P BSE Sensex climbing 0.78%.

    Hong Kong’s unemployment rate came in unchanged at 3% during the three months ending June. Japan reported a trade surplus of JPY 224.04 billion in June, compared to market views for a deficit of JPY 240 billion.

    Economics

    • U.S. initial jobless claims increased by 10,000 to 243,000 in the week ending July 13, compared to market estimates of 230,000.
    • The Philadelphia Fed Manufacturing Index rose to 13.9 in July, recording the strongest level in three months, versus 1.3 in June.
    • The EIA said U.S. natural gas stocks rose by 10 billion cubic feet in the week ended July 12, compared to market estimates of a 28 billion cubic feet gain.

    Now Read This:

    • How To Earn $500 A Month From American Express Stock Ahead Of Q2 Earnings
    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $AGEN
    $CHUY
    $COMM

    CompanyDatePrice TargetRatingAnalyst
    Leslie's Inc.
    $LESL
    1/15/2026$1.50Equal-Weight → Underweight
    Morgan Stanley
    Torrid Holdings Inc.
    $CURV
    10/24/2025Outperform → Mkt Perform
    William Blair
    Abbott Laboratories
    $ABT
    10/10/2025$145.00Buy
    The Benchmark Company
    CommScope Holding Company Inc.
    $COMM
    8/7/2025$20.00Underperform → Buy
    BofA Securities
    CommScope Holding Company Inc.
    $COMM
    8/5/2025$19.00Underperform → Outperform
    Raymond James
    CommScope Holding Company Inc.
    $COMM
    8/5/2025$17.00Underweight → Equal-Weight
    Morgan Stanley
    CommScope Holding Company Inc.
    $COMM
    8/4/2025$12.00Market Perform → Outperform
    Northland Capital
    Abbott Laboratories
    $ABT
    7/18/2025$145.00Hold → Buy
    Jefferies
    More analyst ratings

    $ABT
    $AGEN
    $CHUY
    $COMM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Leslie's Inc.

    DEFA14A - Leslie's, Inc. (0001821806) (Filer)

    2/2/26 4:28:36 PM ET
    $LESL
    Other Specialty Stores
    Consumer Discretionary

    SEC Form DEF 14A filed by Leslie's Inc.

    DEF 14A - Leslie's, Inc. (0001821806) (Filer)

    2/2/26 4:24:23 PM ET
    $LESL
    Other Specialty Stores
    Consumer Discretionary

    Leslie's Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Leslie's, Inc. (0001821806) (Filer)

    1/30/26 8:22:07 AM ET
    $LESL
    Other Specialty Stores
    Consumer Discretionary

    $ABT
    $AGEN
    $CHUY
    $COMM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leslie's downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Leslie's from Equal-Weight to Underweight and set a new price target of $1.50

    1/15/26 8:33:55 AM ET
    $LESL
    Other Specialty Stores
    Consumer Discretionary

    Torrid downgraded by William Blair

    William Blair downgraded Torrid from Outperform to Mkt Perform

    10/24/25 8:59:31 AM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $AGEN
    $CHUY
    $COMM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $ABT
    $AGEN
    $CHUY
    $COMM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $AGEN
    $CHUY
    $COMM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Armen Garo H was granted 5,027 shares, increasing direct ownership by 2% to 320,712 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    2/9/26 4:05:03 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Lindquist Benjamin covered exercise/tax liability with 7 shares and converted options into 19 shares, increasing direct ownership by 0.79% to 1,533 units (SEC Form 4)

    4 - Leslie's, Inc. (0001821806) (Issuer)

    1/29/26 4:15:02 PM ET
    $LESL
    Other Specialty Stores
    Consumer Discretionary

    $ABT
    $AGEN
    $CHUY
    $COMM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

    Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation at the American Association for Cancer Research- Immuno-Oncology (AACR-IO) Conference, taking place in Los Angeles, CA on February 18–21, 2026. The abstract, titled "Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with Fc-enhanced anti–CTLA-4 botensilimab," evaluates how systemic inflammatory markers, tumor microenvironment (TME) immune activity, and peripheral immune cell states are

    2/9/26 1:00:00 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

    Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) System's industry-leading success rate for treating AFib1New data from the FOCALFLEX CE Mark trial demonstrate the safety and efficacy of the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, to significantly reduce AFib episodes for complex cases2ABBOTT PARK, Ill., Feb. 6, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the company's minim

    2/6/26 8:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leslie's, Inc. to Report First Quarter 2026 Financial Results on February 17, 2026

    PHOENIX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Leslie's, Inc. (NASDAQ:LESL), the largest and most trusted direct-to-customer brand in the U.S. pool and spa care industry serving residential customers and pool professionals nationwide, today announced it will release its first quarter 2026 financial results after market close on Tuesday, February 17, 2026. The company will host a conference call at 5:00 p.m. Eastern time on February 17, 2026 to discuss the financial results as well as progress against the company's strategic transformation initiatives. A live webcast of the conference call will be available online at https://ir.lesliespool.com/. A replay of the conference call will be availab

    2/3/26 4:15:00 PM ET
    $LESL
    Other Specialty Stores
    Consumer Discretionary

    $ABT
    $AGEN
    $CHUY
    $COMM
    Leadership Updates

    Live Leadership Updates

    View All

    Leslie's, Inc. Appoints John Hartmann to Board of Directors

    PHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Leslie's, Inc. ((", Leslie', s", or the "Company", NASDAQ:LESL), the largest and most trusted direct-to-customer brand in the U.S. pool and spa care industry serving residential customers and pool professionals nationwide, announced that it has appointed John Hartmann as an independent director to its Board of Directors, effective January 7, 2026. Mr. Hartmann brings nearly 25 years of retail leadership experience where he has executed successful turnaround as a C-suite executive of both public and private companies across diverse industries, including home improvement and home furnishings. He has joined the Board as a Class III Director and will

    1/8/26 8:30:00 AM ET
    $BGSI
    $LESL
    Other Specialty Stores
    Consumer Discretionary

    Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

    Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (AAC) program. BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination, BOT/BAL is being investigated in patients with microsatellite-stable colorectal cancer (MSS CRC), a population that has hi

    11/18/25 8:41:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

    Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challengesCharacter in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through Hamlin's ambassador role for the HeartMates communityMovie premieres on Hallmark Channel on Nov. 28, 2025, during Hallmark's Merry Thanksgiving Weekend during "Countdown to Christmas"ABBOTT PARK, Ill., Nov. 4,

    11/4/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $AGEN
    $CHUY
    $COMM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Torrid Holdings Inc.

    SC 13G - Torrid Holdings Inc. (0001792781) (Subject)

    12/12/24 6:06:52 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Agenus Inc.

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    11/14/24 7:58:18 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by CommScope Holding Company Inc.

    SC 13G/A - CommScope Holding Company, Inc. (0001517228) (Subject)

    11/14/24 1:21:51 PM ET
    $COMM
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ABT
    $AGEN
    $CHUY
    $COMM
    Financials

    Live finance-specific insights

    View All

    Leslie's, Inc. to Report First Quarter 2026 Financial Results on February 17, 2026

    PHOENIX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Leslie's, Inc. (NASDAQ:LESL), the largest and most trusted direct-to-customer brand in the U.S. pool and spa care industry serving residential customers and pool professionals nationwide, today announced it will release its first quarter 2026 financial results after market close on Tuesday, February 17, 2026. The company will host a conference call at 5:00 p.m. Eastern time on February 17, 2026 to discuss the financial results as well as progress against the company's strategic transformation initiatives. A live webcast of the conference call will be available online at https://ir.lesliespool.com/. A replay of the conference call will be availab

    2/3/26 4:15:00 PM ET
    $LESL
    Other Specialty Stores
    Consumer Discretionary

    Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

    Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percentFull-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percentAbbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpointABBOTT PARK, Ill., Jan. 22, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2025. Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-re

    1/22/26 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott hosts conference call for fourth-quarter earnings

    ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

    1/5/26 4:30:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care